The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback